340 related articles for article (PubMed ID: 24975505)
21. Efficacy of Second-Line Chemotherapy in Extrapulmonary Neuroendocrine Carcinoma.
McGarrah PW; Leventakos K; Hobday TJ; Molina JR; Finnes HD; Westin GF; Halfdanarson TR
Pancreas; 2020 Apr; 49(4):529-533. PubMed ID: 32282766
[TBL] [Abstract][Full Text] [Related]
22. A randomised phase II study of modified FOLFIRI.3 vs modified FOLFOX as second-line therapy in patients with gemcitabine-refractory advanced pancreatic cancer.
Yoo C; Hwang JY; Kim JE; Kim TW; Lee JS; Park DH; Lee SS; Seo DW; Lee SK; Kim MH; Han DJ; Kim SC; Lee JL
Br J Cancer; 2009 Nov; 101(10):1658-63. PubMed ID: 19826418
[TBL] [Abstract][Full Text] [Related]
23. A multicenter international randomized phase III study comparing cisplatin in combination with irinotecan or etoposide in previously untreated small-cell lung cancer patients with extensive disease.
Zatloukal P; Cardenal F; Szczesna A; Gorbunova V; Moiseyenko V; Zhang X; Cisar L; Soria JC; Domine M; Thomas M
Ann Oncol; 2010 Sep; 21(9):1810-1816. PubMed ID: 20231298
[TBL] [Abstract][Full Text] [Related]
24. Gemcitabine-based chemotherapy for advanced biliary tract carcinomas.
Abdel-Rahman O; Elsayed Z; Elhalawani H
Cochrane Database Syst Rev; 2018 Apr; 4(4):CD011746. PubMed ID: 29624208
[TBL] [Abstract][Full Text] [Related]
25. Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124.
Lara PN; Natale R; Crowley J; Lenz HJ; Redman MW; Carleton JE; Jett J; Langer CJ; Kuebler JP; Dakhil SR; Chansky K; Gandara DR
J Clin Oncol; 2009 May; 27(15):2530-5. PubMed ID: 19349543
[TBL] [Abstract][Full Text] [Related]
26. Phase II trial of capecitabine/irinotecan and capecitabine/oxaliplatin in advanced gastrointestinal cancers.
Jordan K; Kellner O; Kegel T; Schmoll HJ; Grothey A
Clin Colorectal Cancer; 2004 May; 4(1):46-50. PubMed ID: 15207020
[TBL] [Abstract][Full Text] [Related]
27. Chemotherapy in gastroenteropancreatic (GEP) neuroendocrine carcinomas (NEC): a critical view.
Fazio N; Spada F; Giovannini M
Cancer Treat Rev; 2013 May; 39(3):270-4. PubMed ID: 22819619
[TBL] [Abstract][Full Text] [Related]
28. Influcence of localization of primary tumor on effectiveness of 5-fluorouracil/leucovorin combined with irinotecan and oxaliplatin (FOLFIRINOX) in patients with metastatic pancreatic adenocarcinoma: a retrospective study.
Lorgis V; Chauffert B; Gentil J; Ghiringhelli F
Anticancer Res; 2012 Sep; 32(9):4125-30. PubMed ID: 22993372
[TBL] [Abstract][Full Text] [Related]
29. Post-gemcitabine therapy for patients with advanced pancreatic cancer - A comparative review of randomized trials evaluating oxaliplatin- and/or irinotecan-containing regimens.
Vogel A; Ciardiello F; Hubner RA; Blanc JF; Carrato A; Yang Y; Patel DA; Ektare V; de Jong FA; Gill S
Cancer Treat Rev; 2016 Nov; 50():142-147. PubMed ID: 27676174
[TBL] [Abstract][Full Text] [Related]
30. Liposomal irinotecan plus fluorouracil and leucovorin versus fluorouracil and leucovorin for metastatic biliary tract cancer after progression on gemcitabine plus cisplatin (NIFTY): a multicentre, open-label, randomised, phase 2b study.
Yoo C; Kim KP; Jeong JH; Kim I; Kang MJ; Cheon J; Kang BW; Ryu H; Lee JS; Kim KW; Abou-Alfa GK; Ryoo BY
Lancet Oncol; 2021 Nov; 22(11):1560-1572. PubMed ID: 34656226
[TBL] [Abstract][Full Text] [Related]
31. Cisplatin and etoposide as first-line chemotherapy for poorly differentiated neuroendocrine carcinoma of the hepatobiliary tract and pancreas.
Iwasa S; Morizane C; Okusaka T; Ueno H; Ikeda M; Kondo S; Tanaka T; Nakachi K; Mitsunaga S; Kojima Y; Hagihara A; Hiraoka N
Jpn J Clin Oncol; 2010 Apr; 40(4):313-8. PubMed ID: 20047862
[TBL] [Abstract][Full Text] [Related]
32. Clinical outcomes of locally advanced esophageal neuroendocrine carcinoma treated with chemoradiotherapy.
Honma Y; Nagashima K; Hirano H; Shoji H; Iwasa S; Takashima A; Okita N; Kato K; Boku N; Murakami N; Inaba K; Ito Y; Itami J; Kanamori J; Oguma J; Daiko H
Cancer Med; 2020 Jan; 9(2):595-604. PubMed ID: 31794158
[TBL] [Abstract][Full Text] [Related]
33. Irinotecan combined with gemcitabine, 5-fluorouracil, leucovorin, and cisplatin (G-FLIP) is an effective and noncrossresistant treatment for chemotherapy refractory metastatic pancreatic cancer.
Kozuch P; Grossbard ML; Barzdins A; Araneo M; Robin A; Frager D; Homel P; Marino J; DeGregorio P; Bruckner HW
Oncologist; 2001; 6(6):488-95. PubMed ID: 11743211
[TBL] [Abstract][Full Text] [Related]
34. Five-year data and prognostic factor analysis of oxaliplatin and irinotecan combinations for advanced colorectal cancer: N9741.
Sanoff HK; Sargent DJ; Campbell ME; Morton RF; Fuchs CS; Ramanathan RK; Williamson SK; Findlay BP; Pitot HC; Goldberg RM
J Clin Oncol; 2008 Dec; 26(35):5721-7. PubMed ID: 19001325
[TBL] [Abstract][Full Text] [Related]
35. Nanoliposomal irinotecan plus fluorouracil and folinic acid as a second-line treatment option in patients with metastatic pancreatic ductal adenocarcinoma: a retrospective cohort study.
Park SJ; Kim H; Shin K; Hong TH; Suh JH; Lee MA
BMC Cancer; 2021 Nov; 21(1):1176. PubMed ID: 34732161
[TBL] [Abstract][Full Text] [Related]
36. Prognostic factors and benefits of adjuvant therapy after pancreatoduodenectomy for ampullary adenocarcinoma: Mayo Clinic experience.
Jin Z; Hartgers ML; Sanhueza CT; Shubert CR; Alberts SR; Truty MJ; Muppa P; Nagorney DM; Smyrk TC; Hassan M; Mahipal A
Eur J Surg Oncol; 2018 May; 44(5):677-683. PubMed ID: 29506768
[TBL] [Abstract][Full Text] [Related]
37. Early decrement of serum carbohydrate antigen 19-9 predicts favorable outcome in advanced pancreatic cancer.
Chung KH; Ryu JK; Lee BS; Jang DK; Lee SH; Kim YT
J Gastroenterol Hepatol; 2016 Feb; 31(2):506-12. PubMed ID: 26250642
[TBL] [Abstract][Full Text] [Related]
38. Phase I study of oxaliplatin in combination with gemcitabine, irinotecan, and 5-fluorouracil/leucovorin (G-FLIE) in patients with metastatic solid tumors including adenocarcinoma of the pancreas.
Olszewski AJ; Grossbard ML; Chung MS; Chalasani SB; Malamud S; Mirzoyev T; Kozuch PS
J Gastrointest Cancer; 2013 Jun; 44(2):182-9. PubMed ID: 23208490
[TBL] [Abstract][Full Text] [Related]
39. Induction Chemotherapy Followed by Concurrent Full-dose Gemcitabine and Intensity-modulated Radiation Therapy for Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma.
Badiyan SN; Olsen JR; Lee AY; Yano M; Menias CO; Khwaja S; Wang-Gillam A; Strasberg SM; Hawkins WG; Linehan DC; Myerson RJ; Parikh PJ
Am J Clin Oncol; 2016 Feb; 39(1):1-7. PubMed ID: 26132367
[TBL] [Abstract][Full Text] [Related]
40. A Phase III trial comparing irinotecan and cisplatin with etoposide and cisplatin in adjuvant chemotherapy for completely resected pulmonary high-grade neuroendocrine carcinoma (JCOG1205/1206).
Eba J; Kenmotsu H; Tsuboi M; Niho S; Katayama H; Shibata T; Watanabe S; Yamamoto N; Tamura T; Asamura H; ;
Jpn J Clin Oncol; 2014 Apr; 44(4):379-82. PubMed ID: 24474818
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
